Logo image of CNCE

CONCERT PHARMACEUTICALS INC (CNCE) Stock Fundamental Analysis

NASDAQ:CNCE - Nasdaq - US2060221056 - Common Stock - Currency: USD

8.37  +0.01 (+0.12%)

After market: 8.4 +0.03 (+0.36%)

Fundamental Rating

3

CNCE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. CNCE has a great financial health rating, but its profitability evaluates not so good. CNCE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CNCE has reported negative net income.
CNCE had a negative operating cash flow in the past year.
CNCE Yearly Net Income VS EBIT VS OCF VS FCFCNCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

1.2 Ratios

The profitability ratios for CNCE are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNCE Yearly ROA, ROE, ROICCNCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 -60

1.3 Margins

CNCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNCE Yearly Profit, Operating, Gross MarginsCNCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

CNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNCE has more shares outstanding
CNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNCE Yearly Shares OutstandingCNCE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
CNCE Yearly Total Debt VS Total AssetsCNCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

CNCE has an Altman-Z score of 0.66. This is a bad value and indicates that CNCE is not financially healthy and even has some risk of bankruptcy.
CNCE's Altman-Z score of 0.66 is in line compared to the rest of the industry. CNCE outperforms 58.93% of its industry peers.
CNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.66
ROIC/WACCN/A
WACC9.05%
CNCE Yearly LT Debt VS Equity VS FCFCNCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

CNCE has a Current Ratio of 9.03. This indicates that CNCE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CNCE (9.03) is better than 67.55% of its industry peers.
A Quick Ratio of 9.03 indicates that CNCE has no problem at all paying its short term obligations.
CNCE's Quick ratio of 9.03 is fine compared to the rest of the industry. CNCE outperforms 67.55% of its industry peers.
Industry RankSector Rank
Current Ratio 9.03
Quick Ratio 9.03
CNCE Yearly Current Assets VS Current LiabilitesCNCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CNCE have decreased strongly by -62.12% in the last year.
Looking at the last year, CNCE shows a very negative growth in Revenue. The Revenue has decreased by -99.87% in the last year.
CNCE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 176.94% yearly.
EPS 1Y (TTM)-62.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y45.85%
Revenue growth 5Y176.94%
Sales Q2Q%-98.53%

3.2 Future

CNCE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.00% yearly.
The Revenue is expected to grow by 42.40% on average over the next years. This is a very strong growth
EPS Next Y-22.75%
EPS Next 2Y-10.27%
EPS Next 3Y2.66%
EPS Next 5Y15%
Revenue Next Year-99.69%
Revenue Next 2Y-37.26%
Revenue Next 3Y-0.95%
Revenue Next 5Y42.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CNCE Yearly Revenue VS EstimatesCNCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
CNCE Yearly EPS VS EstimatesCNCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNCE. In the last year negative earnings were reported.
Also next year CNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNCE Price Earnings VS Forward Price EarningsCNCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNCE Per share dataCNCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.27%
EPS Next 3Y2.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNCE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONCERT PHARMACEUTICALS INC

NASDAQ:CNCE (3/3/2023, 8:00:00 PM)

After market: 8.4 +0.03 (+0.36%)

8.37

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02 2023-03-02
Earnings (Next)05-03 2023-05-03
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.52%
Ins Owner Change0%
Market Cap401.95M
Analysts78.18
Price Target11.9 (42.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.85%
Min EPS beat(2)3.95%
Max EPS beat(2)31.75%
EPS beat(4)2
Avg EPS beat(4)-2.61%
Min EPS beat(4)-35.64%
Max EPS beat(4)31.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-82.77%
Min Revenue beat(2)-90.49%
Max Revenue beat(2)-75.04%
Revenue beat(4)0
Avg Revenue beat(4)-78.64%
Min Revenue beat(4)-100%
Max Revenue beat(4)-49.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-32.95%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-43.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9570.22
P/FCF N/A
P/OCF N/A
P/B 3.02
P/tB 3.02
EV/EBITDA N/A
EPS(TTM)-3.21
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)-2.29
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS0
BVpS2.78
TBVpS2.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.03
Quick Ratio 9.03
Altman-Z 0.66
F-Score2
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)23.64%
Cap/Depr(5y)80.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
EPS Next Y-22.75%
EPS Next 2Y-10.27%
EPS Next 3Y2.66%
EPS Next 5Y15%
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y45.85%
Revenue growth 5Y176.94%
Sales Q2Q%-98.53%
Revenue Next Year-99.69%
Revenue Next 2Y-37.26%
Revenue Next 3Y-0.95%
Revenue Next 5Y42.4%
EBIT growth 1Y-142.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.51%
OCF growth 3YN/A
OCF growth 5YN/A